Carlos Dunlap appears to be done with the Cincinnati Bengals. The two-time Pro Bowl defensive end has spent his entire 11-season career with the Bengals, but seemed to reach his breaking point with the franchise on Sunday.
Carlos Dunlap appears to be done with the Cincinnati Bengals. The two-time Pro Bowl defensive end has spent his entire 11-season career with the Bengals, but seemed to reach his breaking point with the franchise on Sunday.
Ghana holds presidential and parliamentary elections on Dec. 7 amid concerns over its rising debt pile, but that has not stopped some investors from buying up its bonds on a bet that the next government will move to repair the public finances. The two main presidential candidates are promising to spend more if they win the tightly contested vote, while the financial fallout of the coronavirus pandemic has pushed up the debt-to-GDP ratio past 70% and prompted the International Monetary Fund to flag the danger of debt distress. Warmer sentiment towards global emerging markets in general after recent vaccine developments have also lifted sentiment.
Passport Software, Inc., Developer of Passport Business Solutions™, Launches New Accounting Software Option - PBS Essentials™, a customizable Accounting Solution for Small Business.
Sleek, an innovative startup that is disrupting the way we wait in line, is excited to announce its partnership with Roaming Hunger, an online marketplace that enables mobility by connecting food trucks with properties, events, and brands. As food trucks and small businesses are fighting against the COVID pandemic, Sleek and Roaming Hunger are providing solutions for these integral businesses of the U.S. economy to retain revenue and succeed despite unfathomable circumstances.
The Mesothelioma Victims Center says, "The Coronavirus will probably make 2020 the worst year for mesothelioma compensation in two decades, and we know for a fact that many people who were diagnosed with mesothelioma this year may have not gone to medical treatment appointments and may have delayed beginning the mesothelioma compensation process. If your husband or dad has just died from confirmed mesothelioma before the compensation process could begin please call attorney Erik Karst of the remarkable law firm of Karst von Oiste at 800-714-0303. Erik Karst is one of the nation's leading mesothelioma attorneys-and he will know exactly how to help a family in this difficult situation. Financial compensation for a person with mesothelioma might exceed a million dollars as Erik Karst is always happy to discuss." www.karstvonoiste.com/
The mayor of Los Angeles, Eric Garcetti, said early Tuesday that the city would reopen a coronavirus testing site at Union Station, a major transit hub, after residents criticized a decision to temporarily close the site during a film shoot.The movie, "He's All That," which features the TikTok star Addison Rae and is a reboot of the 1999 romantic comedy "She's All That," had received approval to film inside and outside the station on Tuesday, the city and county's film office said. About 170 cast and crew members were expected to take part in the movie scenes, the film office said.The reversal came after a homeless outreach and advocacy group called Ktown for All criticized the decision to close the site and shared a copy of an email that it said a resident received on Monday afternoon from the company that operates the testing site. It said that all testing appointments for Tuesday at the station had been canceled because of an event there.Sign up for The Morning newsletter from the New York TimesThe group said that the move showed that the city had misplaced its priorities at a time when hospitalizations for the virus are on the rise, and that the decision to close the site for a day made it more difficult for people who rely on public transportation to get tested."It's truly one of the only COVID testing centers within the city of Los Angeles that is really accessible by public transit," Devon Manney, a spokesman for the group, said in an interview on Monday night. "This is the LA that we are constantly fighting against."Philip Sokoloski, a spokesman for the film office, which is known as FilmLA, said on Monday night that neither the office nor the locations team for the production company had been aware that the station was one of the city's virus testing locations and were not involved in the decision to close the site.Union Station is one of the city's 10 permanent testing sites and five pop-up locations, including one at the North Hollywood Metro station that is on the same rapid transit line as Union Station. City officials did not say who had made the decision to suspend testing at Union Station.In a tweet, Garcetti said the 504 people who were scheduled for a test at Union Station on Tuesday could visit the site as planned. City officials said about 350 daily tests are conducted on average at Union Station, which they said accounted for less than 1% of the more than 35,000 tests that are done every day in Los Angeles.Miramax, which is releasing the film, declined to comment on Monday night.This article originally appeared in The New York Times.(C) 2020 The New York Times Company
(Bloomberg) -- Bitcoin pulled back after making a run at $20,000 on Tuesday amid skepticism over the cryptocurrency’s intense rally.Prices rose to an intraday record of $19,914.33 and then sharply retreated. In an interview with Bloomberg Television, Gary Cohn, a former economic chief to Donald Trump, said the token “lacks some of the basic integrity of a real market” and could eventually fail.“Part of the integrity of a system is knowing who owns it and knowing who has it and knowing why it’s being transferred,” said Cohn, the ex-chief of Goldman Sachs Group Inc. “The Bitcoin system today has no transparency to it. So there are a lot of people that question, why would you need a system that does not have an audit trail.”Bitcoin’s ‘Integrity’ Flaws May Lead to Failure, Gary Cohn SaysBitcoin was down 3.9% at $18,624.18 as of 8:25 a.m. in New York. The digital currency is still up almost 10% this week. The broader Bloomberg Galaxy Crypto Index slid 3.9% on Tuesday.Marcus Swanepoel, chief executive of London-based crypto exchange Luno, said Bitcoin will likely enter the $20,000 to $25,000 range before a significant selloff. Then “it’s likely we’d see a 20% to 30% pullback. This is a predictable pattern and there is no reason to not expect it.”Worth less than $1 back in 2010 when it was touted as currency for purchases, Bitcoin has amassed proponents who argue that its strictly controlled supply and wider investor base show it’s become a store of value. Critics, however, say this year’s 160% rally is a bubble that can’t be supported by claims that digital assets should diversify portfolios and take flows from gold.Bitcoin’s surge this week “is likely a result of major institutional investors joining the bandwagon and purchasing a portion of BTC’s limited supply in the midst of a bull run,” said Gunnar Jaerv, chief operating officer of Hong Kong-based custodian First Digital Trust.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB), today announced that Onur Erzan, will join AB as Head of Global Client Group, effective January 4, 2021.
FloWater introduces the FloFaucet.
Sanity Group, creator of the popular German CBD brand VAAY announced today a follow-on investment of $4.8M US from a host of US and European celebrity investors, including musician, entertainer and Black Eyed Peas front man Will.i.am, US actress Alyssa Milano, German soccer star Mario Goetze and model Stefanie Giesinger along with Bitburger Ventures.
Today, Nextdoor's annual Cheer Map is back to help neighborhoods shine even brighter this season. In partnership with Hallmark Channel's Countdown to Christmas, a favorite holiday tradition with original movies all season long, neighbors can turn to the Cheer Map to share plans to decorate their homes and find which nearby neighborhoods have the most holiday spirit.
According to the latest market research report "5G Chipset Market with COVID-19 Impact by Type (Modem, RFIC), Frequency (Sub-6 GHz, 24- 39 GHz, Above 39 GHz), End-Use (Telecommunication Infrastructure, Mobile Devices, Non-mobile Devices, Automobile), Process Node & Geography - Global Forecast to 2027", published by MarketsandMarkets™, the 5G chipset market is expected to grow from USD 12.8 billion in 2020 to USD 67.2 billion by 2027, at a CAGR of 26.7%. The major factors driving the growth of the 5G chipset market are the growing demand for high-speed internet and broad network coverage, increasing cellular IoT connections, and an increase in mobile data traffic. However, the high cost of the 5G chipset is expected to restrain the growth of the market.
Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. (TSE:LABS.TO) (OTC:MEDIF). Further to Canntab's press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.
According to a new IDC forecast, shipments of desktop and notebook PCs will grow 18.2% year over year in Q4 2020, followed by 1.4% growth in 2021.
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("Mind Cure" or the "Company") is pleased today to announce the appointment of Kelsey Ramsden as President and Chief Executive Officer, effective immediately. With Over 15 years founding, scaling and operating innovative businesses across several industries, Mrs. Ramsden has built multiple eight-figure companies from the ground up. She is an experienced leader and acclaimed entrepreneur, twice recognized as Canada's Top Female Entrepreneur of the Year. After serving as Mind Cure's COO, Mrs. Ramsden steps into the President and CEO role as of December 1, 2020. She possesses a thorough understanding of the mental health industry and a clear vision of where it is going.
TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF) is pleased to announce the hire of Jim Hannon, a seasoned global technology executive, to the role of President of the Altus Analytics business segment. Mr. Hannon will be responsible for leading and executing the market strategy, financial objectives, and operating plans that support the sustained growth of the Company’s Altus Analytics business. He will provide leadership and oversight to all functions for the business unit, including sales and marketing, client success and support, and will work very closely with product development and product management.Mr. Hannon has a proven track record of driving rapid growth and transforming businesses spanning more than three decades of global sales and operational leadership. Having previously worked with Mike Gordon, Chief Executive Officer of Altus Group, he has been a key member of Mr. Gordon’s transition team in a consulting capacity over the past couple of months. As a consultant, he’s worked with a number of international clients with a primary focus on go-to-market strategies, investments and managerial finance and strategy development. During his distinguished career, he served as Chief Commercial Officer at Callcredit Information Group and has held a number of progressively senior leadership roles with global mandates at FICO and Avaya, leading information services and technology companies listed on the New York Stock exchange. Mr. Hannon received a BS in Finance and a BS Management Information Services from Fairfield University and an MBA from the University of Dallas.“Having worked together throughout our careers, I’m confident that Jim will add a lot of value in helping us accelerate our strategic initiatives and execute on our plans to deliver strong operating and financial performance,” said Mr. Gordon. “I value Jim’s customer-centric orientation and collaborative management style and look forward to working together again to capture the significant market opportunity ahead for Altus Group.”“The very attractive growth opportunity for the Altus Analytics business was a natural draw, strengthened by the strong depth in talent across the business,” added Mr. Hannon. “The Altus Analytics business is on the cusp of a new growth phase and I’m excited to be joining at this pivotal time to lead and help define it.”About Altus Group Limited Altus Group Limited is a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry. Our businesses, Altus Analytics and Altus Commercial Real Estate Consulting, reflect decades of experience, a range of expertise, and technology-enabled capabilities. Our solutions empower clients to analyze, gain insight and recognize value on their real estate investments. Headquartered in Canada, we have approximately 2,200 employees around the world, with operations in North America, Europe and Asia Pacific. Our clients include many of the world’s largest commercial real estate industry participants. Altus Group pays a quarterly dividend of $0.15 per share and our shares are traded on the Toronto Stock Exchange under the symbol AIF.For more information on Altus Group, please visit: www.altusgroup.com.FOR FURTHER INFORMATION PLEASE CONTACT:Altus Group Limited Camilla Bartosiewicz Vice President, Investor Relations 416-641-9773 firstname.lastname@example.org
\- Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that a variety of data, including long-term data in the treatment of tuberous sclerosis complex (TSC) and in multiple seizure subtypes for EPIDIOLEX® (cannabidiol) oral solution, will be presented at the virtual American Epilepsy Society (AES) Annual Meeting, taking place December 4-8, 2020. EPIDIOLEX, a pharmaceutical formulation of cannabidiol (CBD), is the first prescription, plant-derived, cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older.New long-term data for people with TSC who enrolled from the EPIDIOLEX expanded access program will be presented for the first time at the meeting, along with other data evaluating the efficacy and safety of EPIDIOLEX for TSC and treatment-resistant epilepsies.“Following FDA approval of EPIDIOLEX in TSC earlier this year, AES is an important opportunity to review additional positive, long-term data,” said Justin Gover, Chief Executive Officer, GW Pharmaceuticals. “Given that the majority of individuals living with TSC experience treatment-resistant epilepsy, we believe there is a need for promising new treatment options and are pleased to present more than three years of TSC patient data in both convulsive and nonconvulsive seizure subtypes.”Meeting activities include:Data Presentations All posters will be available in the ePoster Hall for the duration of AES2020.Long-Term Safety & Efficacy of EPIDIOLEX * Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) for Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC) in an Open-Label Extension (OLE) Trial (GWPCARE6) * Efficacy and Safety of Cannabidiol (CBD) in Patients with Treatment-Resistant Epilepsies in the Expanded Access Program (EAP): Additional Efficacy Data for Convulsive and Nonconvulsive Seizure Subtypes * Long-Term Efficacy and Safety of Cannabidiol (CBD) in Patients with Tuberous Sclerosis Complex (TSC): 4-year Results from the Expanded Access Program (EAP) Post Hoc Analysis of Phase 3 EPIDIOLEX data * Efficacy of Add-On Cannabidiol (CBD) Treatment in Patients with Tuberous Sclerosis Complex (TSC) and a History of Infantile Spasms (IS): Post Hoc Analysis of Phase 3 Trial GWPCARE6 EPIDIOLEX Virtual Booth (accessible in the AES Leadership Exhibitor Hall) December 5-8, 2020About Tuberous Sclerosis Complex (TSC) Tuberous sclerosis complex (TSC) is a rare genetic condition that affects approximately 50,000 individuals in the U.S. and nearly one million people worldwide.1 At least two children born each day will develop TSC, with an estimated prevalence of one in 6,000 newborns.1 The condition causes mostly benign tumors to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs2 and is a leading cause of genetic epilepsy.3 People with TSC may experience a variety of seizure types. One of the most common is infantile spasms that typically present in the first year of life; focal (or partial) seizures are also very common.4 TSC is associated with an increased risk of autism and intellectual disability5 and the severity of the condition can vary widely. In some children the disease is very mild, while others may experience life-threatening complications.2 Epilepsy is present in about 85 percent of patients with TSC and may progress to become intractable to medication.4,6,7 More than 60 percent of individuals with TSC do not achieve seizure control8 with standard treatments such as antiepileptic drugs, epilepsy surgery, ketogenic diet, or vagus nerve stimulation6 compared to 30-40 percent of individuals with epilepsy who do not have TSC who are drug resistant.9,10About EPIDIOLEX® (cannabidiol) oral solution EPIDIOLEX® (cannabidiol) oral solution, a pharmaceutical formulation of highly purified cannabidiol (CBD), is the first in a new class of anti-epileptic medications with a novel mechanism of action, and the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA). In the U.S., EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex has received approval in the European Union under the tradename EPIDYOLEX® for adjunctive use in conjunction with clobazam to treat seizures associated with LGS and Dravet syndrome in patients two years and older. EPIDIOLEX/EPIDYOLEX has received Orphan Drug Designation from the FDA and the EMA for the treatment of seizures associated with Dravet syndrome, LGS and TSC, each of which are severe childhood-onset, drug-resistant syndromes and is under EMA review for the treatment of TSC. Important safety and prescribing information for EPIDIOLEX is available at Epidiolex.com.About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.Important Safety Information Important safety information for Epidiolex is available at Epidiolex.com.Enquiries:U.S. Media Enquiries: Sam Brown Inc. Healthcare Communications Christy Curran Mike Beyer615 414 8668 312 961 2502 ________________________ 1 TS Alliance, What is TSC? https://www.tsalliance.org/about-tsc/what-is-tsc/. Accessed April 15, 2019. 2 NIH Tuberous Sclerosis Fact Sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tuberous-Sclerosis-Fact-Sheet. Accessed November 19, 2019. 3 TS Alliance Website. https://www.tsalliance.org/. Accessed November 19, 2019. 4 Kingswood JC, d'Augeres GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):2. 5 de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157. 6 Tuberous Sclerosis Alliance. Diagnosis, Surveillance, and Management for Healthcare Professionals https://www.tsalliance.org/healthcareprofessionals/diagnosis/. Accessed February 19, 2019. 7 Jeong A, Wong M. Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(9):1443-1449. 8 Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236-1241. 9 Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000;342(5):314–319. 10 French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48 Suppl 1:3-7.
BNY Mellon Wealth Management has announced the appointment of Dawn Guffey to Senior Director, Wealth Management, where she is responsible for managing portfolios as well as providing strategic planning and advice for ultra-high-net-worth-families and their private foundations. Based in Naples, Dawn reports to Market President, Barry McKenzie.
California Resources Corporation (NYSE: CRC), an independent California-based oil and gas exploration and production company, announced that Shawn Kerns, Executive Vice President Operations and Engineering, will be participating in the Cowen 2020 Energy Conference. He will be participating virtually on a panel titled "Carbon Capture Utilization and Storage (CCUS) Opportunities Within Upstream Oil & Gas" at 11:10 a.m. EST on December 4th.
RE/MAX, LLC is partnering with kids to raise funds for Children's Miracle Network (CMN) Hospitals. Starting today, Miracle Masks, a pack of three face coverings featuring artwork by a patient and siblings served by the organization, are available for purchase at rem.ax/MiracleMasks. The final designs were selected after receiving more than 15,000 votes on the RE/MAX Facebook and Instagram accounts. Each pack costs $30, with $15 from each sale donated to the buyer's local CMN Hospital.
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Revelo Resources Corp. (TSXV: RVL) ("Revelo" or the "Company") has acquired ownership of 7,798,747 common shares (representing 19.9% of the outstanding shares) of Pampa Metals Corporation (formerly "Fireswirl Technologies Inc.") of Vancouver, BC. The shares were acquired through the sale by Revelo of eight copper projects in northern Chile to West Pacific Ventures Corp. which was then acquired by Pampa Metals pursuant to a ...